: Opioid overdose antidote Narcan will be available over-the-counter by late summer after FDA approval

Emergent BioSolutions Inc. announced Wednesday that the U.S. Food and Drug Administration approved its opioid overdose-reversing nasal spray, Narcan, for over-the-counter sales.

The news initially sent the drugmaker’s stock EBS soaring as much as 20%, but it has given up most of its gains to be up 6% in midday trading. The FDA’s approval was expected, as an FDA advisory committee had voted unanimously last month in favor of allowing over-the-counter sales of Narcan.

Emergent…